U.S. regulators on Friday put the brakes on their push to speed Pfizer's COVID-19 to children under 5, creating major uncertainty about how soon the shots could become available.
The Food and Drug Administration had urged Pfizer and its partner BioNTech to apply for authorization of extra-low doses of its vaccine for the youngest children before studies were even finished — citing the toll the omicron variant has taken on children.
Next week, FDA advisers were supposed to publicly debate if youngsters should starting getting two shots before it's clear if they'd actually need a third.
But Friday, the FDA reversed course and said it had become clear it needed to wait for data on how well that third shot works for this age group. Pfizer said in a statement that it expected the data by early April.
FDA’s vaccine chief Dr. Peter Marks said he hoped parents would understand that the decision to delay was part of the agency’s careful review and high scientific standards.
“We take our responsibility for reviewing these vaccines very seriously because we’re parents as well,” Marks told reporters during a teleconference.
Pfizer’s early data showed two of the extra-low doses were safe for kids under 5 and strong enough to give good protection to babies as young as 6 months. But once tots reached the preschool age -- the 2- to 4-year-olds -- two shots didn’t rev up enough immunity.
And a study of a third dose isn’t finished yet -- meaning the FDA was considering whether to authorize two shots for now with potentially a third cleared later, something highly unusual.
Friday, the FDA didn’t say exactly what new data Pfizer was providing except that it involved the critical issue of a third dose.
“We believe additional information regarding evaluation of a third dose should be considered as part of our decision-making,” the agency said in a statement.
The nation’s 18 million children under 5 are the only age group not yet eligible for vaccination.
